Abstract
Summary
LV-based cell and gene therapy products refer to therapeutic products that utilize lentiviral vectors (LV) as a delivery system for introducing genetic material into target cells. Lentiviral vectors are commonly used in gene therapy to transfer genes into cells for the treatment of genetic disorders, cancer, and other diseases.
The global LV-Based Cell and Gene Therapy Products market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “LV-Based Cell and Gene Therapy Products Industry Forecast” looks at past sales and reviews total world LV-Based Cell and Gene Therapy Products sales in 2022, providing a comprehensive analysis by region and market sector of projected LV-Based Cell and Gene Therapy Products sales for 2023 through 2029. With LV-Based Cell and Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LV-Based Cell and Gene Therapy Products industry.
This Insight Report provides a comprehensive analysis of the global LV-Based Cell and Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on LV-Based Cell and Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global LV-Based Cell and Gene Therapy Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LV-Based Cell and Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LV-Based Cell and Gene Therapy Products.
United States market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key LV-Based Cell and Gene Therapy Products players cover Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of LV-Based Cell and Gene Therapy Products market by product type, application, key players and key regions and countries.
Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy
Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy
Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Bluebird Bio
Thermo Fisher Scientific
Intas
BMS
Orchard Therapeutics
The global LV-Based Cell and Gene Therapy Products market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “LV-Based Cell and Gene Therapy Products Industry Forecast” looks at past sales and reviews total world LV-Based Cell and Gene Therapy Products sales in 2022, providing a comprehensive analysis by region and market sector of projected LV-Based Cell and Gene Therapy Products sales for 2023 through 2029. With LV-Based Cell and Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LV-Based Cell and Gene Therapy Products industry.
This Insight Report provides a comprehensive analysis of the global LV-Based Cell and Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on LV-Based Cell and Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global LV-Based Cell and Gene Therapy Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LV-Based Cell and Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LV-Based Cell and Gene Therapy Products.
United States market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key LV-Based Cell and Gene Therapy Products players cover Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of LV-Based Cell and Gene Therapy Products market by product type, application, key players and key regions and countries.
Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy
Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy
Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Bluebird Bio
Thermo Fisher Scientific
Intas
BMS
Orchard Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global LV-Based Cell and Gene Therapy Products Market Size 2019-2030
2.1.2 LV-Based Cell and Gene Therapy Products Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for LV-Based Cell and Gene Therapy Products by Country/Region, 2019, 2023 & 2030
2.2 LV-Based Cell and Gene Therapy Products Segment by Type
2.2.1 CAR-T Therapy
2.2.2 Autologous CD34+ Cell Gene Therapy
2.3 LV-Based Cell and Gene Therapy Products Market Size by Type
2.3.1 LV-Based Cell and Gene Therapy Products Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global LV-Based Cell and Gene Therapy Products Market Size Market Share by Type (2019-2024)
2.4 LV-Based Cell and Gene Therapy Products Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic and Testing Laboratories
2.4.3 Academic and Research Organizations
2.4.4 Others
2.5 LV-Based Cell and Gene Therapy Products Market Size by Application
2.5.1 LV-Based Cell and Gene Therapy Products Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global LV-Based Cell and Gene Therapy Products Market Size Market Share by Application (2019-2024)
3 LV-Based Cell and Gene Therapy Products Market Size by Player
3.1 LV-Based Cell and Gene Therapy Products Market Size Market Share by Player
3.1.1 Global LV-Based Cell and Gene Therapy Products Revenue by Player (2019-2024)
3.1.2 Global LV-Based Cell and Gene Therapy Products Revenue Market Share by Player (2019-2024)
3.2 Global LV-Based Cell and Gene Therapy Products Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LV-Based Cell and Gene Therapy Products by Region
4.1 LV-Based Cell and Gene Therapy Products Market Size by Region (2019-2024)
4.2 Global LV-Based Cell and Gene Therapy Products Annual Revenue by Country/Region (2019-2024)
4.3 Americas LV-Based Cell and Gene Therapy Products Market Size Growth (2019-2024)
4.4 APAC LV-Based Cell and Gene Therapy Products Market Size Growth (2019-2024)
4.5 Europe LV-Based Cell and Gene Therapy Products Market Size Growth (2019-2024)
4.6 Middle East & Africa LV-Based Cell and Gene Therapy Products Market Size Growth (2019-2024)
5 Americas
5.1 Americas LV-Based Cell and Gene Therapy Products Market Size by Country (2019-2024)
5.2 Americas LV-Based Cell and Gene Therapy Products Market Size by Type (2019-2024)
5.3 Americas LV-Based Cell and Gene Therapy Products Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC LV-Based Cell and Gene Therapy Products Market Size by Region (2019-2024)
6.2 APAC LV-Based Cell and Gene Therapy Products Market Size by Type (2019-2024)
6.3 APAC LV-Based Cell and Gene Therapy Products Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe LV-Based Cell and Gene Therapy Products Market Size by Country (2019-2024)
7.2 Europe LV-Based Cell and Gene Therapy Products Market Size by Type (2019-2024)
7.3 Europe LV-Based Cell and Gene Therapy Products Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa LV-Based Cell and Gene Therapy Products by Region (2019-2024)
8.2 Middle East & Africa LV-Based Cell and Gene Therapy Products Market Size by Type (2019-2024)
8.3 Middle East & Africa LV-Based Cell and Gene Therapy Products Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global LV-Based Cell and Gene Therapy Products Market Forecast
10.1 Global LV-Based Cell and Gene Therapy Products Forecast by Region (2025-2030)
10.1.1 Global LV-Based Cell and Gene Therapy Products Forecast by Region (2025-2030)
10.1.2 Americas LV-Based Cell and Gene Therapy Products Forecast
10.1.3 APAC LV-Based Cell and Gene Therapy Products Forecast
10.1.4 Europe LV-Based Cell and Gene Therapy Products Forecast
10.1.5 Middle East & Africa LV-Based Cell and Gene Therapy Products Forecast
10.2 Americas LV-Based Cell and Gene Therapy Products Forecast by Country (2025-2030)
10.2.1 United States Market LV-Based Cell and Gene Therapy Products Forecast
10.2.2 Canada Market LV-Based Cell and Gene Therapy Products Forecast
10.2.3 Mexico Market LV-Based Cell and Gene Therapy Products Forecast
10.2.4 Brazil Market LV-Based Cell and Gene Therapy Products Forecast
10.3 APAC LV-Based Cell and Gene Therapy Products Forecast by Region (2025-2030)
10.3.1 China LV-Based Cell and Gene Therapy Products Market Forecast
10.3.2 Japan Market LV-Based Cell and Gene Therapy Products Forecast
10.3.3 Korea Market LV-Based Cell and Gene Therapy Products Forecast
10.3.4 Southeast Asia Market LV-Based Cell and Gene Therapy Products Forecast
10.3.5 India Market LV-Based Cell and Gene Therapy Products Forecast
10.3.6 Australia Market LV-Based Cell and Gene Therapy Products Forecast
10.4 Europe LV-Based Cell and Gene Therapy Products Forecast by Country (2025-2030)
10.4.1 Germany Market LV-Based Cell and Gene Therapy Products Forecast
10.4.2 France Market LV-Based Cell and Gene Therapy Products Forecast
10.4.3 UK Market LV-Based Cell and Gene Therapy Products Forecast
10.4.4 Italy Market LV-Based Cell and Gene Therapy Products Forecast
10.4.5 Russia Market LV-Based Cell and Gene Therapy Products Forecast
10.5 Middle East & Africa LV-Based Cell and Gene Therapy Products Forecast by Region (2025-2030)
10.5.1 Egypt Market LV-Based Cell and Gene Therapy Products Forecast
10.5.2 South Africa Market LV-Based Cell and Gene Therapy Products Forecast
10.5.3 Israel Market LV-Based Cell and Gene Therapy Products Forecast
10.5.4 Turkey Market LV-Based Cell and Gene Therapy Products Forecast
10.6 Global LV-Based Cell and Gene Therapy Products Forecast by Type (2025-2030)
10.7 Global LV-Based Cell and Gene Therapy Products Forecast by Application (2025-2030)
10.7.1 GCC Countries Market LV-Based Cell and Gene Therapy Products Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis LV-Based Cell and Gene Therapy Products Product Offered
11.1.3 Novartis LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Bluebird Bio
11.2.1 Bluebird Bio Company Information
11.2.2 Bluebird Bio LV-Based Cell and Gene Therapy Products Product Offered
11.2.3 Bluebird Bio LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bluebird Bio Main Business Overview
11.2.5 Bluebird Bio Latest Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Information
11.3.2 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Product Offered
11.3.3 Thermo Fisher Scientific LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Thermo Fisher Scientific Main Business Overview
11.3.5 Thermo Fisher Scientific Latest Developments
11.4 Intas
11.4.1 Intas Company Information
11.4.2 Intas LV-Based Cell and Gene Therapy Products Product Offered
11.4.3 Intas LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Intas Main Business Overview
11.4.5 Intas Latest Developments
11.5 BMS
11.5.1 BMS Company Information
11.5.2 BMS LV-Based Cell and Gene Therapy Products Product Offered
11.5.3 BMS LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 BMS Main Business Overview
11.5.5 BMS Latest Developments
11.6 Orchard Therapeutics
11.6.1 Orchard Therapeutics Company Information
11.6.2 Orchard Therapeutics LV-Based Cell and Gene Therapy Products Product Offered
11.6.3 Orchard Therapeutics LV-Based Cell and Gene Therapy Products Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Orchard Therapeutics Main Business Overview
11.6.5 Orchard Therapeutics Latest Developments
12 Research Findings and Conclusion